Table 4.
Secondary prevention for 65 year-olds (all numbers per person)
| Drug cost (€) | CVD cost (€) | QALYs | ICER (Δ€/ΔQALY) | |
|---|---|---|---|---|
| Diabetics | ||||
| Standard | — | 64 872 | 4.67 | — |
| Ezetimibe | 3701 | 64 816 | 5.22 | 6544 |
| Alirocumab | 60 937 | 62 348 | 5.91 | Dominated |
| Evolocumab | 63 468 | 61 495 | 6.05 | 68 386 |
| HeFH | ||||
| Standard | — | 37 679 | 5.85 | — |
| Ezetimibe | 4863 | 35 489 | 6.85 | 2654 |
| Alirocumab | 81 406 | 30 036 | 7.84 | Dominated |
| Evolocumab | 84 646 | 28 695 | 8.01 | 63 174 |
| Statin Intolerant | ||||
| Standard | — | 38 106 | 7.07 | — |
| Ezetimibe | 5459 | 36 237 | 7.62 | 6588 |
| Alirocumab | 88 304 | 31 016 | 8.44 | Dominated |
| Evolocumab | 91 176 | 29 923 | 8.56 | 84 428 |
| Misc. High Risk | ||||
| Standard | — | 38 594 | 7.55 | — |
| Ezetimibe | 5799 | 36 311 | 8.05 | 6969 |
| Alirocumab | 90 182 | 32 439 | 8.59 | Dominated |
| Evolocumab | 92 841 | 31 525 | 8.69 | 128 191 |
Secondary prevention indicates all patients have a history of myocardial infarction.
Standard treatment reflects whatever statin regimen the patients were on prior to initiation of PCSK9 or ezetimibe therapy. No drug cost was used for standard treatment; it was assumed that statin regimens would not change according to treatment and would therefore have no bearing on an incremental comparison of costs.